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Chronic intermittent hypoxia during sleep (IH), as occurs in sleep apnea, promotes systemic insulin
resistance. Resveratrol (Resv) has been reported to ameliorate high-fat diet-induced obesity, in-
flammation, and insulin resistance. To examine the effect of Resv on IH-induced metabolic dys-
function,malemicewere subjected to IHor roomair conditions for 8weeks and treatedwitheither
Resv or vehicle (Veh). Fasting plasma levels of glucose, insulin, and leptin were obtained, homeo-
static model assessment of insulin resistance index levels were calculated, and insulin sensitivity
tests (phosphorylatedAKT [also knownasprotein kinaseB]/totalAKT)wereperformed in 2 visceral
white adipose tissue (VWAT) depots (epididymal [Epi] and mesenteric [Mes]) along with flow
cytometry assessments for VWATmacrophages and phenotypes (M1 andM2). IH-Veh and IH-Resv
mice showed initial reductions in food intake with later recovery, with resultant lower body
weights after 8 weeks but with IH-Resv showing better increases in body weight vs IH-Veh. IH-Veh
and IH-Resvmiceexhibited lower fastingglucose levels, butonly IH-Vehhad increasedhomeostatic
model assessment of insulin resistance index vs all 3 other groups. Leptin levels were preserved in
IH-Vehbutwere significantly lower in IH-Resv.ReducedVWATphosphorylated-AKT/AKTresponses
to insulin emerged in both Mes and Epi in IH-Veh but normalized in IH-Resv. Increases total mac-
rophage counts and inM1toM2ratiosoccurred in IH-VehMesandEpi comparedall other 3groups.
Thus, Resv ameliorates food intake andweight gain during IH exposures andmarkedly attenuates
VWAT inflammation and insulin resistance, thereby providing a potentially useful adjunctive ther-
apy for metabolic morbidity in the context of sleep apnea. (Endocrinology 156: 437–443, 2015)
Intermittent hypoxia during sleep (IH) is one of the hall-marks of obstructive sleep apnea (OSA) and induces a
wide range of morbid consequences, including excessive
daytime sleepiness and cognitive, mood, and neurobehav-
ioral deficits (1–6), as well as cardiovascular dysfunction
(7–10). IH also imposes adverse metabolic consequences,
such as hyperlipidemia and insulin resistance, even in lean
mice, along with structural and cellular remodeling of ad-
ipose tissue (11–18). Themetabolic consequences of sleep
apnea have been causally linked to increased prevalence
and clinical deterioration of type 2 diabetes aswell aswith
increased homeostatic model assessment of insulin resis-
tance index (HOMA) inboth children andadults (19–24).
Furthermore, acute exposures to IH inhealthyhumansub-
jects elicited alterations in insulin sensitivity (24). How-
ever, the mechanisms underlying these alterations remain
incompletely elucidated. Evidence indicates that disrup-
tion of pancreatic -cell function and integrity may be
operational in IH-induced alterations in glucose homeo-
stasis (25–27)but is insufficient toaccount for the systemic
and tissue-specific insulin resistance, such as seen in adi-
pose tissue (28). Globally, it is currently assumed that the
altered insulin sensitivity can be ascribed to IH-induced
increases in oxidative stress and activation of inflamma-
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torypathways that lead toheightened sympathetic tone, and
altered cardiovascular and metabolic parameters, as
well as manifesting as a prooxidative status (eg, in-
creased lipid peroxides, enhanced nicotinamide adenine
dinucleotide phosphate oxidase, mitochondrial dys-
function, and diminished activities of superoxide dis-
mutases), and augmented inflammatory status (11,
30–32).
In the last decade, resveratrol (Resv) has emerged as po-
tent antiobesogenic compound that affords protection
against high-fat-diet-induced obesity and insulin resistance
(33–35). Although the mechanisms underlying Resv-in-
ducedbeneficialeffectsonsystemicandtissue-specific insulin
sensitivity remain to be fully delineated, beneficial effects of
Resvhave emergedonaging, inflammation, andmetabolism
andareputativelyascribedtoactivationofthe lysinedeacety-
lase, sirtuin1, cAMP,orAMP-activatedproteinkinasepath-
ways (36–38). We hypothesized that administration of this
compound would dampen IH-induced systemic insulin re-
sistance and potentially reduce visceral white adipose tissue
(VWAT) macrophage infiltration and, thus, attenuate insu-
lin resistance in adipocytes.
Materials and Methods
Animals
Adult male C57BL/6J mice from Jackson Laboratories (8 wk
old, 22 g), were housed in groups of 5 (to prevent isolation
stress) in standard clear polycarbonate cages and allowed to ac-
climatize to their surroundings.Mice were fed normal chow diet
andwater ad libitum andmaintained in a 12-hour light, 12-hour
dark cycle (light on 7 AM to 7 PM) at a constant temperature (26
1°C).Mice were randomly assigned to IH exposures or room air
(RA) conditions and to treatment with Resv or vehicle (Veh)
(control) for 8 weeks.
Mice receiveddrinkingwater containing0.01%Resv (Sigma-
Aldrich). This amount of Resv is approximately 10 times the
amount found in 1Lof redwine andwas initially dissolved in 0.4
mL of absolute ethanol and then added to 100 mL of drinking
water. The Veh group received the same volume of drinking
water containing an identical concentration of ethanol. All mice
had free access to the drinking solution, andmice consumed 3–4
mL of the drinking fluid daily, with the daily consumption of
Resv being 0.3–0.4 mg/mouse (ie, a relatively high dose of the
compound with demonstrated efficacy) (39).
Animal experiments were performed according to protocols
approved by the Institutional Animal Committee University of
Chicago of the University of Chicago and are in close agreement
with theNational Institutes of Health Guide in the Care and Use
of Animals. All efforts were made to minimize animal suffering
and to reduce the number of animals used.
Intermittent hypoxia exposures
Mice were placed in identical commercially designed cham-
bers (30 20 20 inches; Oxycycler A44XO; BioSpherix) op-
erated under a 12-hour light, 12-hour dark cycle (7 AM to 7 PM)
for a period of 8 weeks. Programmed gas concentrations were
circulated into each chamber, and an internal O2 analyzer mea-
sured the O2 concentration continuously. Deviations from the
fixed concentrations were automatically corrected by a comput-
erized system of solenoid valves controlling gas outlets adding
either N2 or O2. Ambient CO2 in the chamber was maintained
at less than 0.01%, and humidity was also maintained at 40%–
50% by circulating the gas through a freezer and silica gel. Am-
bient temperature was kept at 26°C as described previously by
Gozal and coworkers (1, 15) and Gozal et al (40). Mice were
subjected for 12 hours during daylight to intermittent hypoxia/
normoxia cycles of 3-minute duration (hypoxia, nadir of FiO2:
6.4% for 90 s alternating with normoxia [fractional inspired
oxygen concentration, FiO2, 21%] for 90 s). This IH profile is
associated with reproducible nadir of oxyhemoglobin satura-
tions in the 65%–72%range.Normoxic (FiO2, 21%) conditions
were used during the 12-hour lights-off period. Control animals
were exposed to circulatingRA (FiO2, 21%)during daylight and
lights-off period.
Food consumption and body weight
Food consumption per cage was registered daily, always at
the same timeof the day (middle of the light period).Animal food
consumptionwas thencalculatedbydividing thedaily cage chow
useby thenumberofmice in the cage. Bodyweightwasmeasured
every other day always at the same time of the day (middle of the
light cycle period). Body weight gain was determined by sub-
tracting the body weight on first day of IH exposure from the
body weight on subsequent days.
ELISA and insulin sensitivity assays
Mice were fasted for 3 hours (4–7 AM) with water available
ad libitum and were then euthanized. Venous blood was col-
lected into EDTA-containing tubes, immediately centrifuged in
at4°C, and frozenat80°Cuntil further analyses.Bloodglucose
was immediately assessedusing anOneTouchUltra2 glucometer
(Life Scan, Inc). Insulin and leptin assays were carried out using
ELISAkits (Millipore) according to themanufacturer’s protocol.
The linear range of the insulin assay was 0.2–10 ng/mL, with the
limit of sensitivity at 0.2 ng/mL (35pM) and intra- and interin-
dividual coefficients of variation up to 8.8%and 17.6%, respec-
tively, at lower concentrations (ie, 0.32 ng/mL). Similarly for the
leptin assay, the linear range was 0.2 up to 30 ng/mL with the
sensitivity threshold at 0.05 ng/mL (3.13pM). The intraassay
variation coefficient was up to 1.7% at high concentrations of
leptin (17.60 ng/mL) and 6.8% of interindividual coefficient of
variation at low concentrations (ie, 1.66 ng/mL). The homeo-
static model (HOMA) was then calculated as the product of
glucose and insulin levels divided by 405.
Adipocyte insulin sensitivity was assessed in adipocytes de-
rived from epididymal (Epi) and mesenteric (Mes) fat tissue de-
pots as described previously (41). Briefly, primary adipocytes
were isolated by collagenase digestion and flotation centrifuga-
tion. They were then incubated with insulin at various concen-
trations at 37°C for 10 minutes with gentle vortexing every 2
minutes. After 2 washes with cold Krebs-Ringer buffer, cells
were lysed in Laemmli buffer and assessed using Western blot
analysis for phosphorylated and total Akt (protein kinase B)
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(antiphospho-Akt [Ser473] and anti-Akt; Cell Signaling
Technology).
Isolation of stromal-vascular fraction (SVF) and
flow cytometry analysis
Epi fat pads andMes adipose tissues were dissected, isolated,
and then minced in Krebs-Ringer buffer supplemented with 1%
BSA followed by incubation with collagenase (1 mg/mL; Wor-
thington Biochemical Corp) at 37°C for 45 minutes with shak-
ing. Cell suspensions were filtered through a 100-mmesh and
centrifuged at 500g for 5minutes to separate floating adipocytes
from the SVF pellet. SVF pellets were then resuspended in flow
cytometry buffer (PBS plus 2% fetal bovine serum), and 106 cells
were used for staining with fluorescence-conjugate primary an-
tibodies or control IgGs at 4°C for 30 minutes. Cells were then
washed twice and analyzed with a flow cytometer (Canto II; BD
Biosciences).Data analysiswas performedusing the FlowJo soft-
ware (Tree Star). Adipose tissue macrophages were defined as
F4/80 and CD11b cells, from which M1 and M2 macro-
phages were identified as CD11c or CD206 cells, respec-
tively. Please see Table 1 for list of antibody reagents.
Statistical analysis
All values are expressed as mean SD. ANOVA procedures
followed by post hoc tests and Student’s t tests were used to
compare the results between 4 treatment groups as appropriate,
using SPSS statistical software (version 21.0; SPPS, Inc). In all
cases, 2-tailed P  .05 was considered to achieve statistical
significance.
Results
Food intake and weight gain
Mice exposed to IH exhibited initial decreases in food
intake that began within the first 24 hours after the initi-
ation of IH and were followed by progressive recovery to
control levels within the first week (n  12/condition;
Figure 1. Food intake and weight gain in IH and RA-exposed mice treated with either Resv or Veh for 8 weeks. A, Mean food intake per mouse/d
over 8 weeks; green color indicates IH and open circles indicate Resv treatment. Two-way ANOVA (treatment  condition) F statistic  8.18; P 
.001. B, Mean overall daily food intake for the 8-week period per mouse; P  .001. C, Mean weekly changes in body weight over the 8-week
period; two-way ANOVA (treatment  condition) F statistic  12.74; P  .001. D, Overall changes in body weight; P  .001. E, Mean weights of
Epi fat pads; P  .001, n  12–24/treatment group.
Table 1. Information on All Antibodies and Reagents
Used in Current Study
Treg
CD3-FITC Clone 145-2C11 100306 Biolegend
CD4-PE Clone RM4-4 116006 Biolegend
CD8-APC/Cy7 Clone 53-6.7 100714 Biolegend
CD25-PerCP/Cy5.5 Clone PC61 102030 Biolegend
FoxP3-APC Clone FJK-16s 17-5773 eBioscience
Macrophages
CD11b-PB Clone M1/70 101224 Biolegend
F4/80-PE/Cy7 Clone BM8 123113 Biolegend
CD11c-APC/Cy7 Clone N418 117324 Biolegend
CD206-PE Clone C068C2 141705 Biolegend
Gr1-PerCP Clone RB6-8C5 108428 Biolegend
WBC
CD3-FITC Clone 145-2C11 100306 Biolegend
CD4-PE Clone RM4-4 116006 Biolegend
CD8-APC/Cy7 Clone 53-6.7 100714 Biolegend
Gr1-PerCP Clone RB6-8C5 108428 Biolegend
CD115-APC Clone AFS98 135509 Biolegend
CD11b-PB Clone M1/70 101224 Biolegend
CD4-PE Clone RM4-4 116006 Biolegend
CD8-APC/Cy7 Clone 53-6.7 100714 Biolegend
CD25-PerCP/Cy5.5 Clone PC61 102030 Biolegend
FoxP3-APC Clone FJK-16s 17-5773 eBioscience
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P  .001) (Figure 1A). However, IH-Veh-exposed mice
showed overall reduced food intake compared with all 3
other groups (Figure 1B). IH-Veh mice displayed poorest
weight at the end of the 8-week period, with IH-Resv-
exposed mice showing improved weight gain, albeit still
lower than RA-treated mice (n  24 mice/treatment
group;P .001) (Figure 1,CandD).
Notably, IH-Veh-exposed mice
showed most significant reductions
in epididymis fat pad weights with
some recovery occurring in IH-Resv
(n  12/group) (Figure 1E).
Effect of Resv on systemic
insulin and leptin levels and on
visceral adipose tissue insulin
resistance
Overall fasting glycemic levels were
similar across the 4 treatment groups.
However, in IH-Vehmice, higher fast-
ingHOMAlevelsdue tohigher insulin
levels emerged after 8 weeks of IH,
with such changes being abrogated in
IH-Resv-treated mice (Figure 2). Sim-
ilarly, plasma leptin levels were unal-
tered in IH-Veh mice compared with
RA-exposed groups, but IH-Revmice
showedmarkedly reducedplasma lep-
tin levels (Figure 2).
Insulin sensitivity in VWAT, as
assessed by Akt phosphorylation in
response to insulin in both Mes and
Epi adipose tissue depots, indicated
the presence of insulin resistance af-
ter 8weeks of IHbut only in IH-Veh-
treated mice. Overall, the findings
were very similar for either Mes or
Epi. In contrast, there were signifi-
cant improvements in adipose tissue
insulin sensitivity in IH-exposed
mice treated with Resv (n  8/treat-
ment group) (Figure 2).
Resv protects from IH-induced
increases in macrophages and
polarization in VWAT
IH for aperiodof8weeks induced
marked increases in the global num-
ber of macrophages present in the
SVF of both Mes and Epi (Figure 3).
Such increases consisted primarily of
increases in the proportion of mac-
rophages exhibiting the proinflam-
matory M1 phenotype (CD11c; n  8/group, P  .01)
(Figure 3) and reciprocal reductions in macrophages with
M2 polarity (CD206; n 8/group, P .01) (Figure 3),
such that theM1 toM2ratiowasmarkedly increased after
IH (n 8/group; P .01) (Figure 3). IH-induced changes
Figure 2. Metabolic effects of Resv in mice. A, Plasma levels of glucose, insulin, and leptin in IH
and RA-exposed mice after fasting for 3 hours and treated with either Resv or Veh for 8 weeks.
B, Example of Epi adipose tissue insulin sensitivity assay as demonstrated by changes in
phosphorylated Akt (p-AKT) and total Akt (total-AKT) after adding 0nM or 5nM insulin to the
medium (upper panel). The lower panel illustrates the summary of 6 separate experiments for
p-AKT to total-AKT ratios between 0nM and 5nM insulin. Two-way ANOVA: *, P  .01 IH-Veh vs
3 other treatment groups. Please note that the findings for Mes adipose tissue were nearly
identical (data not shown).
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inMes andEpiVWATdepotmacrophagesweremarkedly
attenuated in Resv-treated mice exposed to IH.
Discussion
This study confirms previous findings that chronic IH ex-
posures imposed during the predominant sleep period in
mice lead to the emergence of systemic insulin resistance
and increased VWAT inflammation (11–18). Further-
more, we now show that treatment with Resv improved
the reduced food intake patterns and weight gain associ-
ated with IH-exposures and restored insulin responsive-
nesswhile normalizing the inflammatory processeswithin
VWATdepots. Furthermore, Resv administrationwas as-
sociated with marked reductions in circulating leptin lev-
els, suggesting increased leptin receptor sensitivity.
Beforewediscuss someof themajor implications of our
findings, some methodological issues deserve specific
mention. First, we have implemented an IH experimental
paradigm that provides highly reproducible findings and,
most importantly, mimics frequently encountered pat-
terns of episodic hypoxia occurring in diseases such as
OSA (15). In this context, the initial prominent reductions
in food consumption and overall di-
minished nutrient intake exhibited
by IH-exposedmice is similar to that
previously reportedbyus (15) aswell
as by others (42) and may reflect rel-
ative leptin receptor resistance in-
duced by IH in the context of an
overall catabolic state (43).Notably,
Resv treatment improved IH-medi-
ated deceleration in weight gain dur-
ing the duration of the experiments,
suggesting that the both central and
peripheral metabolic and orexigenic
pathways modulated by IH are af-
fected by this compound, an effect
that is not apparent duringnormoxic
conditions. Secondly, as in previous
studies (15), we opted not to expose
mice to a high-fat diet regimen or to
use transgenic mouse models of obe-
sity or insulin resistance, because we
aimed to examine the isolated effects
of Resv on IH-induced metabolic
dysfunction. Thirdly, we exposed
our mice to a realistic and imple-
mentable yet relatively higher dose
ofResv that has already exhibited fa-
vorableoutcomes in eithermetabolic
or low-grade chronic inflammatory
processes (44–47). There is no doubt that future studies,
possibly in patients with sleep apnea, can investigate
whether Rev supplements at lower doses effectively trans-
late into similar results as those described here. Finally, we
should point out that this study was observational in na-
ture and therefore does not provide insights into which of
themultiplemechanisms that have been attributed toResv
effects (33–39) was predominantly involved in current
findings. Notwithstanding, the current experimental ap-
proach convincingly indicates that IH mimicking the ep-
isodic hypoxia of sleep apnea induces adipose tissue dys-
function, macrophage infiltration, and phenotypic shift,
as well as insulin resistance, all of which are ameliorated
by administration of Resv.
Notably, although Resv treatment did not completely
restore the overall reduced food intake and weight gain
associated with IH, it reversed both systemic and insulin
resistance. Thus, the potential use of Resv as a dietary
supplement in patients with OSA who also manifest sub-
clinical evidence of insulin resistance may ultimately im-
prove metabolic control and potentially prevent the in-
creased incidence of diabetes in this population (20).
Furthermore, the beneficial impact of Resv on the inflam-
Figure 3. Macrophage cell recruitment in SVF of VWAT in IH and RA-exposed mice treated with
either Resv or Veh for 8 weeks. A, Total macrophage count expressed as percentage of cells
isolated from SVF. B, M1 macrophage count expressed as percentage of total macrophage
count. C, M2 macrophage count expressed as percentage of total macrophage count. D, M1 to
M2 ratio. n  8/experimental group; two-way ANOVA: *, P  .01 IH-Veh vs 3 other treatment
groups; #, IH-Resv vs RA groups.
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matory phenotype of the SVF of 2 VWAT depots would
suggest that the increased activation of inflammatory
pathways elicited by IH (18, 49) was reversed by admin-
istration of Resv. Notably the effects of IH and those of
Resv treatment were remarkably similar in both adipose
tissue depots. We here not only explored a previously de-
scribed inflammatory pathway, namelymacrophages, but
also their polarity shifts. The compelling evidence sup-
porting a major role for adipose tissue macrophage infil-
tration in the context of obesity and metabolic derange-
ments is mimicked by chronic IH in the absence of an
obesogenic diet.We can further infer basedon theputative
roles of macrophage phenotypes (50) that the magnitude
of the primarily M1 macrophage infiltration, along with
the reciprocal M2 macrophage reduction, is a major de-
terminant of the degree of insulin resistance induced by
long-term IH (51–55). Indeed, concurrent with the in-
creased presence of macrophages in IH-exposed adipose
tissues, a phenomenon thatmay bemediated by transcrip-
tion factors such as hypoxia-inducible factors or nuclear
factor B (27, 48, 56), there was also a shift in their phe-
notypes, such that increased populations of M1 macro-
phages along with reduced M2 macrophage cell counts
occurred and were reversed by administration of Resv.
Thus, our current findings conclusively confirm that
chronic IH, a frequent occurrence in the context of OSA
andother respiratorydiseases, is an important contributor
to the metabolic dysfunction associated with these disor-
ders, most likely via effects on visceral adipose tissue, even
when food intake is reduced. Furthermore,wehave shown
that concurrent administration of Resv improves the re-
ductions in food intake andweight gain and is particularly
effective at reversing the metabolic disturbances induced
by IH, most likely by abrogating visceral adipose tissue
inflammation. Thus, regular use of dietary supplements,
such as Resv, may provide a useful adjunct therapy aimed
at reducing the early stages of metabolic dysfunction in
OSA.
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